AH057 是一种口服有效的 JAK1 和 JAK2 抑制剂,可阻断 IL-6、IFN-α 和 IFN-γ 诱导的 JAK/STAT 信号,降低癌细胞增殖、侵袭和克隆形成,并诱导凋亡 (apoptosis) 和 G1 期细胞周期阻滞,可用于宫颈癌研究。
产品编号: MS-S29387 CAS No.: 118499-11-9 分子式: C17H22N2O 分子量: 270.37
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

AH057 是一种口服有效的 JAK1 和 JAK2 抑制剂,可阻断 IL-6、IFN-α 和 IFN-γ 诱导的 JAK/STAT 信号,降低癌细胞增殖、侵袭和克隆形成,并诱导凋亡 (apoptosis) 和 G1 期细胞周期阻滞,可用于宫颈癌研究。

生物实验数据

生物活性 AH057 is an orally active JAK1 and JAK2 inhibitor that blocks IL-6-, IFN-α-, and IFN-γ-induced JAK/STAT signaling, reduces cancer cell proliferation, invasion, and colony formation, and induces apoptosis and G1 phase cell cycle arrest, making it useful for cervical cancer research.
IC50 & Target

JAK1

 

JAK2

 

STAT3

 

体外研究
(In Vitro)

AH057 (1 μM; 2 h) 在 HeLa 细胞中选择性抑制 p-JAK2、p-STAT3,不影响 p-AKT、p-p65 蛋白磷酸化。
AH057 (0.1-20 μM; 2 h) 剂量依赖性抑制 HeLa、DU145、HepG2 细胞 JAK2/STAT3 磷酸化,其中宫颈癌细胞 HeLa 敏感性最高。
AH057 (HeLa 1 μM, DU145 10 μM, HepG2 20 μM; 0.25-3 h) 时间依赖性抑制 JAK2 和 STAT3 活化,并在 15 min 内快速抑制 JAK2 磷酸化。
AH057 (预处理 1 h; 随后使用 250 ng/mL IL-6 或 IFN-α 共刺激 1 h) 在 HeLa、DU145 和 HepG2 可阻断 IL-6、IFN-α、IFN-γ 刺激引起的 JAK1/JAK2/TYK2、STAT1/STAT3 磷酸化激活。
AH057 (预处理 1 h; 随后使用 250 ng/mL IL-6 或 IFN-α 共刺激 4 h) 在 HeLa、DU145 和 HepG2 下调 IL-6 诱导的 SOCS3,和IFN-α 诱导的 IRF1 和 IRF2 mRNA 表达。
AH057 (20 μM; 4 h) 抑制过表达 JAK1/JAK2/TYK2 激酶 JH1 结构域的 HEK293T 细胞总酪氨酸磷酸化及 STAT1/STAT3 活化。
AH057 (0.0005-100 μM; 72 h) 抑制多种癌细胞系活力,其中宫颈癌细胞系 HeLa、CaSki 和 SiHa 的 IC50 分别为 0.62 μM、11.28 μM 和 17.53 μM。
AH057 (0.2-100 μM;48 h) 抑制 HeLa、CaSki、SiHa 宫颈癌细胞侵袭能力,对正常 HcerEpic 细胞无明显抑制作用。
AH057 (125-250 nM;14 天) 剂量依赖性减少宫颈癌细胞克隆形成数量。
AH057 (200 nM, 10 μM) 体外抑制宫颈癌细胞 (Hela, CaSki) 划痕迁移能力。
AH057 (0.5-20 μM;24 h) 诱导 HeLa、CaSki 细胞凋亡与 G1/S 周期阻滞;HeLa 细胞 G1 期比例从对照组 69.95% 上升至 1 μM 处理组 81.9%。
AH057 (500 nM + SGI-1027 (MS-W68225) 1 μM;24 h) 联合 SGI-1027 在 HeLa 细胞中产生协同凋亡与更强 G1 期阻滞,进一步下调 Cyclin D1/A2/B1、Bcl-XL、Survivin,上调活化 Caspase-3 与裂解 PARP,联合治疗表现出某些基因(BAX、BCL-XL、BCL-2、MDM2、Cyclin A2、Cyclin D3 和 CDK2)的协同下调。
AH057 通过基于 docking 的虚拟筛选被鉴定为 JAK 抑制剂候选物,分子对接显示 AH057 可结合 JAK2 活性位点口袋,并通过疏水相互作用以及与 Tyr931 和 Leu932 等关键残基形成氢键发挥结合作用。

Western Blot Analysis

Cell Line: HeLa
Concentration: 10 μM
Incubation Time: 4 h
Result: Showed the strongest inhibitory activity among nine top-ranking compounds against JAK2 phosphorylation and STAT3 phosphorylation.
Reduced pTyr1007/1008-JAK2 and pTyr705-STAT3 levels while maintaining total JAK2 and STAT3 protein levels.

Western Blot Analysis

Cell Line: HeLa, DU145, HepG2
Concentration: HeLa (0.1, 0.5, 1.0, 1.5, 2.0 μM); DU145, HepG2 (1, 5, 10, 15, 20 μM)
Incubation Time: 2 h
Result: Reduced pTyr1007/1008-JAK2, pTyr705-STAT3 and pSer727-STAT3 levels in a dose-dependent manner.
HeLa cells showed higher AH057 sensitivity than DU145 and HepG2 cells.
Reduced JAK2 and STAT3 phosphorylation in both DU145 and HepG2 cells, confirming inhibition of JAK2/STAT3 signaling across multiple cancer cell lines.

Western Blot Analysis

Cell Line: HeLa, DU145, HepG2
Concentration: 1 μM in HeLa cells; 10 μM in DU145 cells; 20 μM in HepG2 cells
Incubation Time: 0.25, 0.5, 1, 2, 3 h
Result: Time-dependently inhibited JAK2 and STAT3 activation.
Rapidly reduced JAK2 phosphorylation within 15 min, supporting direct inhibition of JAK2 kinase activity.

Western Blot Analysis

Cell Line: HeLa, DU145, HepG2
Concentration: 1 μM in HeLa cells; 10 μM in DU145 cells; 20 μM in HepG2 cells
Incubation Time: 1 h pretreatment; IL-6, IFN-α or IFN-γ stimulation at 250 ng/mL for 1 h
Result: Blocked IL-6-induced JAK1, JAK2 and STAT3 phosphorylation.
Decreased IFN-α-induced JAK1, JAK2, TYK2, STAT1 and STAT3 phosphorylation.
Reduced IFN-γ-induced JAK1, JAK2, STAT1 and STAT3 phosphorylation.

Real Time qPCR

Cell Line: HeLa, DU145, HepG2
Concentration: 1 μM in HeLa cells; 10 μM in DU145 cells; 20 μM in HepG2 cells
Incubation Time: 1 h pretreatment; IL-6, IFN-α or IFN-γ stimulation at 250 ng/mL for 4 h
Result: Suppressed IL-6-induced SOCS3 mRNA transcription and IFN-α-induced IRF1 mRNA transcription in all three cell lines.

Western Blot Analysis

Cell Line: HEK293T cells overexpressing JAK1-JH1, JAK2-JH1 or TYK2-JH1
Concentration: 20 μM
Incubation Time: 4 h
Result: Reduced total tyrosine phosphorylation driven by overexpressed JAK1-JH1, JAK2-JH1 or TYK2-JH1.
Suppressed downstream STAT1 and STAT3 phosphorylation, supporting direct inhibition of JAK kinase domains.

Cell Viability Assay

Cell Line: HcerEpic, HeLa, CaSki, SiHa, SK-OVR-3, ES-2, BT549, Huh7, Hep3B, HepG2, DU145, NCI-87, AGS, AsPC-3, U251
Concentration: 0.0005-100 μM
Incubation Time: 72 h
Result: Inhibited the viability of multiple cancer cell lines.
HeLa cells were the most sensitive tested cancer cells, with an IC50 of 0.62 μM.
CaSki and SiHa cervical cancer cells showed IC50 values of 11.28 μM and 17.53 μM, respectively.
Other cancer cell lines showed IC50 values ranging from 14.06 μM to 48.96 μM.

Cell Invasion Assay

Cell Line: HcerEpic, HeLa, CaSki, SiHa
Concentration: 100 μM in HcerEpic cells; 200 nM in HeLa cells; 10 μM in CaSki and SiHa cells
Incubation Time: 48 h
Result: Impaired invasion ability of HeLa, CaSki and SiHa cervical cancer cells.
Did not significantly reduce invasion of normal HcerEpic cells under the tested condition.

Cell Proliferation Assay

Cell Line: HcerEpic, HeLa, CaSki, SiHa
Concentration: 50, 100 μM in HcerEpic cells; 125, 250 nM in HeLa cells; 1, 5 μM in CaSki and SiHa cells
Incubation Time: 14 days
Result: Dose-dependently reduced colony formation in HeLa, CaSki and SiHa cervical cancer cells.
Did not significantly reduce colony formation of normal HcerEpic cells at 50 μM or 100 μM.

Cell Viability Assay

Cell Line: HeLa
Concentration: 500 nM; 1 μM SGI-1027 (MS-W68225)
Incubation Time: 48 h
Result: Synergistically reduced HeLa cell viability.
The combined effect of AH057 and SGI-1027 was time-dependent, and combination treatment induced stronger cell death than either single compound.

Apoptosis Analysis

Cell Line: HeLa
Concentration: 500 nM; 1 μM SGI-1027 (MS-W68225)
Incubation Time: 4 h
Result: Increased both early and late apoptotic cell populations.
Combination treatment induced a higher percentage of apoptotic cell death than either AH057 or SGI-1027 alone.

Western Blot Analysis

Cell Line: HeLa
Concentration: 500 nM; 1 μM SGI-1027 (MS-W68225)
Incubation Time: 24 h
Result: Enhanced cleaved PARP and cleaved caspase-3 levels.
Reduced the anti-apoptotic proteins Bcl-XL and Survivin, with stronger effects under combination treatment than either single compound.
Decreased Cyclin D1, Cyclin A2 and Cyclin B1 protein levels.
Combination treatment further potentiated the decrease in these cell-cycle regulators compared with AH057 alone.

Cell Cycle Analysis

Cell Line: HeLa
Concentration: 500 nM; 1 μM SGI-1027 (MS-W68225)
Incubation Time: 24 h
Result: Induced G1/S cell-cycle arrest. SGI-1027 alone increased S-phase accumulation, whereas combination treatment induced a higher G1-phase population than either single compound.
体内研究
(In Vivo)

AH057 (50 mg/kg; 口服灌胃; 每日一次; 连续 30 天) 在 HeLa 移植瘤 BALB/c 裸鼠模型中抑制肿瘤生长、诱导肿瘤细胞凋亡并降低肿瘤细胞增殖。
AH057 (50 mg/kg/day; 口服灌胃; 连续 24 天) 与 SGI-1027 (MS-W68225; 50 mg/kg/day; 口服灌胃) 联用在 HeLa 移植瘤 BALB/c 裸鼠模型中抑制肿瘤生长,且化合物的心脏和肾脏毒性不明显。

Animal Model: Female 3-4 week-old BALB/c nude mice were subcutaneously injected with HeLa cells (1.5 × 106 cells/mouse) in the xenograft model
Dosage: 50 mg/kg/day
Administration: Oral gavage (p.o.); once daily; for 30 days
Result: Significantly reduced HeLa xenograft tumor volume.
Was well tolerated with no mortality and no significant body weight loss during the trial.
Increased TUNEL-positive apoptotic cells in tumor tissues.
Reduced Ki67-positive tumor cells, indicating decreased tumor-cell proliferation.
Animal Model: Female 3–4 week-old BALB/c nude mice were subcutaneously inoculated with 1.5 × 106 HeLa cells per mouse to establish xenograft combination models and combined with 50 mg/kg/day SGI-1027
Dosage: 50 mg/kg/day
Administration: Oral gavage (p.o.); once daily; for 24 days
Result: Suppressed HeLa xenograft tumor growth under oral administration.
Combination treatment showed stronger tumor-growth inhibition than vehicle treatment.
Cardiac and renal toxicity was inappreciable according to the accompanying toxicity data.

化学信息

分子量 270.37
分子式 C17H22N2O
CAS No. 118499-11-9

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础